838 related articles for article (PubMed ID: 21719005)
1. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
Lie Fong S; Schipper I; de Jong FH; Themmen AP; Visser JA; Laven JS
Fertil Steril; 2011 Aug; 96(2):459-63. PubMed ID: 21719005
[TBL] [Abstract][Full Text] [Related]
2. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
3. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
4. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation.
Anderson RA; Groome NP; Baird DT
Clin Endocrinol (Oxf); 1998 May; 48(5):577-84. PubMed ID: 9666869
[TBL] [Abstract][Full Text] [Related]
5. Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection.
Wunder DM; Guibourdenche J; Birkhäuser MH; Bersinger NA
Fertil Steril; 2008 Dec; 90(6):2203-10. PubMed ID: 18291376
[TBL] [Abstract][Full Text] [Related]
6. Anti-Müllerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome.
El-Mazny A; Abou-Salem N
Gynecol Endocrinol; 2013 Sep; 29(9):826-9. PubMed ID: 23855354
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of circulating anti-Müllerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study.
Mahran A; Abdelmeged A; El-Adawy AR; Eissa MK; Shaw RW; Amer SA
J Clin Endocrinol Metab; 2013 Oct; 98(10):4170-5. PubMed ID: 23979947
[TBL] [Abstract][Full Text] [Related]
8. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
Zhang F; Liu XL; Rong N; Huang XW
J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
[TBL] [Abstract][Full Text] [Related]
10. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
[TBL] [Abstract][Full Text] [Related]
11. Relationship between inhibin A and B, estradiol and follicle growth dynamics during ovarian stimulation in normo-ovulatory women.
Hohmann FP; Laven JS; de Jong FH; Fauser BC
Eur J Endocrinol; 2005 Mar; 152(3):395-401. PubMed ID: 15757856
[TBL] [Abstract][Full Text] [Related]
12. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle.
Lockwood GM; Muttukrishna S; Groome NP; Matthews DR; Ledger WL
J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683
[TBL] [Abstract][Full Text] [Related]
13. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.
Kunt C; Ozaksit G; Keskin Kurt R; Cakir Gungor AN; Kanat-Pektas M; Kilic S; Dede A
Arch Gynecol Obstet; 2011 Jun; 283(6):1415-21. PubMed ID: 21562964
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome.
Catteau-Jonard S; Pigny P; Reyss AC; Decanter C; Poncelet E; Dewailly D
J Clin Endocrinol Metab; 2007 Nov; 92(11):4138-43. PubMed ID: 17698904
[TBL] [Abstract][Full Text] [Related]
15. The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome.
Li J; Li R; Yu H; Zhao S; Yu Y; Qiao J
Syst Biol Reprod Med; 2015 Apr; 61(2):103-9. PubMed ID: 25329139
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
Lie Fong S; Laven JSE; Duhamel A; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
[TBL] [Abstract][Full Text] [Related]
17. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women.
Wunder DM; Bersinger NA; Yared M; Kretschmer R; Birkhäuser MH
Fertil Steril; 2008 Apr; 89(4):927-33. PubMed ID: 17603052
[TBL] [Abstract][Full Text] [Related]
18. Inhibin B levels on cycle day 3 to predict the ovulatory response in women with PCOS undergoing ovulation induction via low dose step-up gonadotropin protocol.
Kökçü A; Turhan E; Cetinkaya MB; Yanik F; Alper T; Malatyalioğlu E
Arch Gynecol Obstet; 2004 Dec; 270(4):255-9. PubMed ID: 13680268
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.
Bayrak A; Terbell H; Urwitz-Lane R; Mor E; Stanczyk FZ; Paulson RJ
Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152
[TBL] [Abstract][Full Text] [Related]
20. Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women.
Wachs DS; Coffler MS; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2007 May; 92(5):1871-4. PubMed ID: 17299061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
